Jaguar Health (NASDAQ:JAGX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGXGet Rating) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Zacks Investment Research cut shares of Jaguar Health from a hold rating to a sell rating in a report on Wednesday, May 18th.

JAGX opened at $0.40 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 1.49 and a quick ratio of 1.24. The company has a market cap of $30.73 million, a price-to-earnings ratio of -0.31 and a beta of 1.82. The firm has a 50 day simple moving average of $0.51 and a 200 day simple moving average of $0.84. Jaguar Health has a fifty-two week low of $0.34 and a fifty-two week high of $6.84.

Jaguar Health (NASDAQ:JAGXGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.19). Jaguar Health had a negative return on equity of 319.63% and a negative net margin of 1,023.99%. During the same quarter in the prior year, the company earned ($0.30) EPS. As a group, analysts expect that Jaguar Health will post -0.84 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Buckingham Strategic Wealth LLC acquired a new position in Jaguar Health during the fourth quarter valued at approximately $33,000. Jump Financial LLC acquired a new position in shares of Jaguar Health in the third quarter valued at approximately $67,000. Renaissance Technologies LLC acquired a new position in shares of Jaguar Health in the first quarter valued at approximately $1,079,000. Virtu Financial LLC boosted its holdings in shares of Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 99,073 shares during the period. Finally, Morgan Stanley acquired a new position in shares of Jaguar Health in the first quarter valued at approximately $159,000. Hedge funds and other institutional investors own 11.91% of the company’s stock.

About Jaguar Health (Get Rating)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

See Also

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.